The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 05, 2021

Filed:

May. 29, 2014
Applicant:

The Regents of the University of California, Oakland, CA (US);

Inventors:

David V. Schaffer, Danville, CA (US);

Melissa A. Kotterman, Oakland, CA (US);

Bum-Yeol Hwang, Moraga, CA (US);

James T. Koerber, San Francisco, CA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C12N 15/86 (2006.01); C07H 21/02 (2006.01); C12N 7/00 (2006.01); C07K 14/005 (2006.01); A61K 35/761 (2015.01); A61K 35/76 (2015.01); C12N 15/10 (2006.01); A01K 67/00 (2006.01);
U.S. Cl.
CPC ...
C12N 7/00 (2013.01); A61K 35/76 (2013.01); A61K 35/761 (2013.01); A61K 48/005 (2013.01); C07K 14/005 (2013.01); C12N 15/1058 (2013.01); C12N 15/86 (2013.01); C12N 2750/14122 (2013.01); C12N 2750/14143 (2013.01);
Abstract

The present disclosure provides infectious recombinant adeno-associated virus (rAAV) virions that comprise a variant capsid protein and a heterologous nucleic acid. The present disclosure further provides the variant adeno-associated virus (AAV) capsid proteins (and/or a nucleic acid encoding the variant AAV capsid proteins), which confer to an infectious rAAV virion an increased resistance to human AAV neutralizing antibodies. The present disclosure further provides host cells comprising an infectious rAAV virion and/or a nucleic acid encoding a subject variant AAV capsid protein. The present disclosure further provides methods of delivering a heterologous nucleic acid to a target cell where the target cell is contacted with a subject infectious rAAV virion. The present disclosure further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.


Find Patent Forward Citations

Loading…